MedTrace Logo

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

NCT01318941 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30490

Last updated 2016-05-23

No results posted yet for this study

Summary

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.

Conditions

  • Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
  • Wet Age Related Macular Degeneration
  • Diabetic Macular Edema
  • Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab

OTHER

Ranibizumab

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • China
  • Colombia
  • Costa Rica
  • Czechia
  • Dominican Republic
  • Ecuador
  • Egypt
  • France
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • India
  • Ireland
  • Israel
  • Italy
  • Japan
  • Malaysia
  • Mexico
  • Netherlands
  • Panama
  • Peru
  • Poland
  • Portugal
  • Russia
  • Saudi Arabia
  • Singapore
  • Slovakia
  • Slovenia
  • South Korea
  • Spain
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01318941 on ClinicalTrials.gov